Analytical Solutions and Method Development Considerations for Quantitative Bioanalytical Oligonucleotide Studies

Importance of the Topic

Oligonucleotide-based therapies offer precise modulation of gene expression, addressing diseases refractory to traditional small molecules or biologics. Accurate quantitation of these drugs in biological matrices is critical to characterize pharmacokinetics, assess safety margins, and support regulatory requirements in drug development.

Study Aims and Overview

This application note presents a validated bioanalytical workflow for quantifying nusinersen, an 18-mer antisense oligonucleotide (ASO), in rat plasma. The objectives were to streamline sample preparation with a kit-based approach, achieve sub-ng/mL sensitivity via IP-RP UPLC–MS/MS, and demonstrate robust calibration over a broad dynamic range.

Methodology and Instrumentation

• Sample preparation: OligoWorks SPE Microplate Kit incorporating Proteinase K digestion and mixed-mode WAX cleanup.
• Chromatography: Waters ACQUITY Premier UPLC System with Premier Oligonucleotide C18 Column (1.7 µm, 2.1 × 50 mm); mobile phases containing HFIP/DIPEA, freshly prepared daily to preserve MS sensitivity.
• Mass spectrometry: Xevo TQ Absolute XR triple quadrupole operating in negative ESI with MRM transitions (precursor m/z 890 → product m/z 95 and 393) optimized for specificity and signal-to-noise.
• Data handling: waters_connect for Quantitation Software to automate method creation, acquisition, processing, exception-focused review, and reporting.

Key Results and Discussion

• Calibration linearity over 0.1–1000 ng/mL (R² > 0.99, 1/x weighting), covering four orders of magnitude.
• Lower limit of quantification (LLOQ): 0.1 ng/mL with blank response <20% of LLOQ.
• Accuracy for calibration standards: 91.5–105.7%; precision (%CV): 0.5–10.8%.
• Quality control (QC) performance at low (0.375 ng/mL), mid, and high (750 ng/mL) levels: accuracy 104.2–112.5%; %CV 0.8–7.3%.
• Optimization of SPE wash solvent: 30% methanol wash yielded >100% recovery and <2% matrix effects, compared to 10% methanol which gave 80% recovery and 22% matrix effects.
• MRM transition 890 → 393 provided clean specificity in plasma despite matrix peaks in other channels.

Benefits and Practical Applications

• Standardized OligoWorks kit reduces development time and variability in oligonucleotide extraction.
• High sensitivity detection at sub-nanogram levels supports pharmacokinetic and safety studies.
• Premier UPLC hardware and inert column surface minimize non-specific adsorption, enhancing recovery and LLOQ.
• Automated workflows in waters_connect simplify method setup, data processing, and compliance with regulated bioanalysis.

Future Trends and Opportunities

The expanding pipeline of oligonucleotide and RNA therapeutics will drive further innovation in sample preparation, including ion-pairing-free methods, high-throughput automation, and multiplexed assays. Integration with high-resolution MS and machine learning for data analysis may enhance sensitivity, specificity, and throughput in complex biological matrices.

Conclusion

The described IP-RP UPLC–MRM methodology, combined with a kit-based SPE workflow and automated software, delivers robust quantitation of nusinersen in rat plasma at sub-ng/mL levels. The approach offers excellent linearity, precision, and accuracy across wide dynamic ranges, facilitating efficient bioanalytical support for oligonucleotide drug development.

Reference

• Takakusa H, et al. Nucleic Acid Ther. 2023;33(2):83–94.
• Yuan L, et al. Molecules. 2023;28(4).
• Liu A, et al. Int J Mol Sci. 2022;23(24):15474.
• Damase TR, et al. Front Bioeng Biotechnol. 2021;9:2021.
• Hayashi Y, Sun Y. J Am Soc Mass Spectrom. 2024;35(9):2034–2037.
• McCarthy SM, Pourshahian S. Handbook of Analysis of Oligonucleotides. CRC Press; 2011.
• Azarani A, Hecker KH. Nucleic Acids Res. 2001;29(2):E7.
• McGinnis AC, et al. J Chromatogr B. 2012;883–884:76–94.
• Guimaraes GJ, Bartlett MG. Future Sci OA. 2021;7(10):FSO753.
• Donegan M, et al. J Chromatogr A. 2022;1666.
• Hannauer F, et al. Anal Sci Adv. 2022;3(3-4):90–102.
• Malarvannan M, et al. J Chromatogr A. 2024;1732:465226.
• Nuckowski Ł, et al. J Chromatogr B. 2018;1090:90–100.
• Geary RS, et al. Adv Drug Deliv Rev. 2015;87:46–51.
• Geary RS. Expert Opin Drug Metab Toxicol. 2009;5(4):381–391.
• Yu RZ, et al. J Pharm Sci. 2004;93(1):48–59.
• Chen B, Bartlett MG. J Chromatogr A. 2013;1288:73–81.
• Zhang X, et al. Heliyon. 2024;10(10):e31213.
• Xu T, et al. Biomed Chromatogr. 2025;39(7):e70138.
• Tanna N, Lee M, Trudeau M. Waters Application Note. 2023.
• Araya M, et al. Waters Application Note. 2025.
• Chiriboga CA, et al. Neurology. 2016;86(10):890–897.
• Waters Corporation. Oligonucleotide Separation Technology Standard Manual.
• Waters Corporation. IonHance HFIP Care & Use Manual.
• IDT Resuspension Calculator. 2025.
• Waters Corporation. OligoWorks SPE Kits and Components Guide.
• Guimaraes GJ, et al. J Am Soc Mass Spectrom. 2023;34(12):2691–2699.
• Waters Corporation. Premier Columns Promotion.
• Huang M, et al. J Chromatogr A. 2021;1648:462184.
• Kilanowska A, et al. J Chromatogr A. 2020;1622:461100.
• Studzińska S, et al. J Chromatogr B. 2017;1040:282–288.